Hansoh Pharmaceutical Group Co Ltd
03692
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Contact
287 Xiangke Road
Pudong New District
Shanghai201210
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,347
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,190.90 | 19.30 | -0.21% |
| CAC 40 | 8,327.86 | 91.88 | 1.12% |
| DAX 40 | 24,044.22 | 301.78 | 1.27% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,609.06 | 26.10 | 0.25% |
| HKSE | 26,180.37 | 308.05 | 1.19% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 58,184.34 | 306.95 | 0.53% |
| NZX 50 Index | 13,066.62 | 49.36 | 0.38% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,987.90 | 23.50 | -0.26% |
| SSE Composite Index | 4,043.06 | 16.43 | 0.41% |